Seelos therapeutics announces proposed public offering

New york , nov. 28, 2023 /prnewswire/ -- seelos therapeutics, inc. (nasdaq: seel) ("seelos"), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced that it has commenced an underwritten public offering of shares of its common stock (or pre-funded warrants to purchase shares of its common stock in lieu thereof) and accompanying common warrants to purchase shares of its common stock. seelos also intends to grant the underwriters a 45-day option to purchase up to an additional 15% of the aggregate number of shares of its common stock (or pre-funded warrants) and/or the common warrants to be sold in the offering on the same terms and conditions.
SEEL Ratings Summary
SEEL Quant Ranking